RaySearch Laboratories AB (publ)

RaySearch Laboratories maintains a debt-to-equity ratio of 0.65 and a current ratio of 1.2, indicating moderate leverage and liquidity. The company holds SEK 435.2 million in cash and equivalents, but this is offset by SEK 498.96 million in long-term debt, resulting in a net cash position of negative SEK 63.76 million. Free cash flow for the period was SEK 49.89 million, while capital expenditures amounted to SEK -118.75 million, suggesting a focus on asset investment. Profitability metrics show a return on equity of 8% and a return on assets of 2.98%, both below the industry median for Advanced Medical Equipment & Technology firms. Operating income of SEK 79.32 million and net income of SEK 61.43 million reflect a healthy margin, but gross profit of SEK 295.12 million on revenue of SEK 318.87 million suggests a narrow gross margin of approximately 92.5%. The company operates as a single business segment, with all revenue derived from software licenses and service contracts. Geographic exposure is not disclosed in the input data, but the company is headquartered in Sweden and operates globally, with no indication of revenue concentration in any single region. RaySearch Laboratories reported revenue of SEK 318.87 million for the period, with no prior-year data provided. Analysts project a mean price target of SEK 330.00, with a median of SEK 330.00 and a strong buy recommendation from one analyst. The company's growth trajectory is not quantified in the input data, but the positive free cash flow and strong operating income suggest a stable financial position. Risk factors include a medium liquidity risk due to the net cash position and a low dilution risk, as shares outstanding remain unchanged between basic and diluted counts. No dilution sources are disclosed in the input data, and no recent events such as filings or transcripts are provided for further context.